Cantor Fitzgerald Boosts Healthpeak Properties (NYSE:DOC) Price Target to $23.00

Key Points

• Cantor Fitzgerald raised Healthpeak Properties’ price target to $23 from $20 while maintaining a “neutral” rating, implying approximately 5.5% upside from the reported $21.80 share price.
• Analyst sentiment remains cautious: four analysts rate the stock a Buy and 15 rate it Hold, resulting in an overall “Hold” consensus and an average price target of $20.97.
• Healthpeak exceeded quarterly expectations, reporting EPS of $0.08 versus a $0.03 estimate and revenue of $771.58 million versus $725.64 million; revenue increased 11.1% year over year.

Healthpeak Properties (NYSE:DOC - Get Free Report) had its target price increased by stock analysts at Cantor Fitzgerald from $20.00 to $23.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a "neutral" rating on the real estate investment trust's stock. Cantor Fitzgerald's price objective indicates a potential upside of 5.49% from the company's current price.

Other analysts have also recently issued research reports about the company. Barclays started coverage on Healthpeak Properties in a research report on Tuesday, July 7th. They set an "equal weight" rating and a $23.00 price objective for the company. BMO Capital Markets increased their price objective on shares of Healthpeak Properties from $20.00 to $24.00 and gave the stock an "outperform" rating in a research note on Monday, June 15th. Weiss Ratings raised Healthpeak Properties from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, May 8th. Robert W. Baird boosted their target price on shares of Healthpeak Properties from $19.00 to $21.00 and gave the stock an "outperform" rating in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Healthpeak Properties from a "sell" rating to a "hold" rating in a research note on Sunday, May 10th. Four research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. According to MarketBeat.com, Healthpeak Properties presently has an average rating of "Hold" and an average price target of $20.97.

Healthpeak Properties Trading Up 0.8%

NYSE DOC opened at $21.80 on Thursday. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15. The stock has a 50-day moving average of $21.12 and a 200-day moving average of $18.76. The firm has a market cap of $15.03 billion, a PE ratio of 62.29, a price-to-earnings-growth ratio of 3.36 and a beta of 1.01. Healthpeak Properties has a 1-year low of $15.70 and a 1-year high of $22.95.

Healthpeak Properties (NYSE:DOC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The real estate investment trust reported $0.08 EPS for the quarter, beating the consensus estimate of $0.03 by $0.05. Healthpeak Properties had a net margin of 8.24% and a return on equity of 2.87%. The firm had revenue of $771.58 million during the quarter, compared to the consensus estimate of $725.64 million. During the same period in the prior year, the firm posted $0.46 earnings per share. The company's quarterly revenue was up 11.1% compared to the same quarter last year. Healthpeak Properties has set its FY 2026 guidance at 1.730-1.770 EPS. As a group, sell-side analysts forecast that Healthpeak Properties will post 1.75 EPS for the current year.

Insider Activity

In other news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the transaction, the insider directly owned 7,636 shares in the company, valued at approximately $148,520.20. This represents a 59.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is owned by company insiders.

Institutional Investors Weigh In On Healthpeak Properties

Large investors have recently bought and sold shares of the business. Norges Bank bought a new stake in Healthpeak Properties during the fourth quarter worth approximately $153,550,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Healthpeak Properties by 694.6% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 8,016,692 shares of the real estate investment trust's stock valued at $153,520,000 after purchasing an additional 7,007,777 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Healthpeak Properties by 60.3% in the 1st quarter. Bank of New York Mellon Corp now owns 15,456,420 shares of the real estate investment trust's stock worth $253,949,000 after purchasing an additional 5,815,189 shares during the period. Fuller & Thaler Asset Management Inc. increased its position in shares of Healthpeak Properties by 19.2% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust's stock valued at $476,744,000 after purchasing an additional 4,776,056 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Healthpeak Properties by 214.0% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,230,551 shares of the real estate investment trust's stock valued at $98,050,000 after buying an additional 2,883,382 shares during the period. Institutional investors own 93.57% of the company's stock.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source